➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Moodys
AstraZeneca
Baxter
Medtronic

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 8,003,762

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,003,762
Title:Monoclonal antibody to CD166 and method for production thereof
Abstract: CD166 is a cell adhesion molecule belonging to an immunoglobulin superfamily that is expressed in an excessive amount on the tumor surface. If an monoclonal antibody specifically binding to the CD166 is obtained, it becomes possible to suppress growth of tumor cells, detect the cells, and supply a therapeutic drug thereto specifically. However, because the CD166 proteins are very similar to each other among mammals, it was not possible to obtain an antibody to human CD166, by immunizing, for example, mice with the human CD166. The antibody was prepared by immunizing mice with a purified avian CD166 protein. The antibody was found to be adsorbed on human and mouse CD166 proteins in vitro as well as in vivo and to have an action to suppress tumor growth in mice.
Inventor(s): Tsukamoto; Yasuhiro (Takatsuki, JP)
Assignee: Japan Science and Technology Agency (Saitama, JP) Osaka Prefecture University Public Corporation (Osaka, JP)
Application Number:12/085,674
Patent Claims:see list of patent claims

Details for Patent 8,003,762

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Octapharma Usa Inc CUTAQUIG immunoglobulin g SOLUTION 125668 1 2019-05-03   Start Trial Japan Science and Technology Agency (Saitama, JP) Osaka Prefecture University Public Corporation (Osaka, JP) 2025-11-29 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Moodys
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.